Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute and Visiting Professor at McGill University, shared Abi Siva’s, Associate Professor and Director of Medical Oncology at MUSC Health Hematology Oncology at Hollings Cancer Center, post on X, adding:
“My take:
- We don’t treat metastatic disease to shrink the tumor, but to prolong OS and maintain/improve QoL.
- That said, some patients with HER2+ do get cured. Could longer T-DXd increase that rate? To be determined.
- Shared decision making is key to personalize the duration of 1L T-DXd/P!”
Quoting Abi Siva’s post:
“This analysis is powerful: patients who reach CR do so at ~8.4 months, stay on T-DXd for ~28 months, and many responses are still ongoing at cutoff. This really makes us question whether T-DXd needs to be continued beyond CR or deep PR, or if we should transition to a more easily tolerated maintenance approach instead. Ongoing trials like DIMITHER and other induction-maintenance studies will help answer this.”
Other articles featuring Paolo Tarantino and Abi Siva on OncoDaily.